{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:07:27Z","timestamp":1789726047087,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CorMedix"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hospitalized adults with candidemia or invasive candidiasis (C\/IC) often remain inpatient to complete daily intravenous echinocandin therapy. Rezafungin, a once-weekly echinocandin, may facilitate earlier discharge in clinically stable patients. We evaluated its potential economic impact from a US hospital perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A decision-analytic probabilistic model compared 2 treatment-discharge strategies in 100 hypothetical hospitalized adults with C\/IC who had reached clinical stability and were otherwise dischargeable: continued inpatient daily echinocandin therapy until observed discharge versus administration of a single 400\u2005mg dose of rezafungin with earlier discharge. The rezafungin strategy incorporated earlier discharge distributions from a multicenter US study. Costs included antifungal acquisition, inpatient hospitalization during the final 4 hospital days, and peripherally inserted central catheter (PICC)-related costs (2026 US dollars). Deterministic, threshold, and probabilistic sensitivity analyses (10 000 Monte Carlo simulations) were performed, focusing on excess hospital costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base case, mean excess cost was lower with rezafungin than standard of care (SOC) (\u2212$412 vs $708 per patient), corresponding to savings of $1120 per patient. Savings were greater when SOC required PICC placement (\u2212$2269) versus no PICC placement (\u2212$851). Rezafungin was associated with higher costs when no earlier discharge occurred (+$3471) or discharge occurred only 1 day earlier (+$1475), but became cost saving with \u22652 days earlier discharge (\u2212$556 at 2 days, \u2212$2903 at 3 days, and \u2212$5313 at \u22654 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once-weekly rezafungin reduced hospital costs versus daily echinocandins when it enabled discharge \u22652 days earlier, with greater savings when PICC placement was avoided.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag563","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:52:55Z","timestamp":1788616375000},"source":"Crossref","is-referenced-by-count":0,"title":["A US Hospital-Perspective Decision-Analytic Model of Once-Weekly Rezafungin Versus Daily Echinocandin Therapy in Hospitalized Adults With Candidemia or Invasive Candidiasis: Potential Cost Savings From Earlier Discharge"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences , Albany, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-549X","authenticated-orcid":false,"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026091805324048100_ofag563-B1"},{"key":"2026091805324048100_ofag563-B2","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1093\/cid\/ciaa193","article-title":"Burden of candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026091805324048100_ofag563-B3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091805324048100_ofag563-B4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026091805324048100_ofag563-B5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jiac.2021.06.017","article-title":"Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: a systematic review and meta-analysis","volume":"27","author":"Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"2026091805324048100_ofag563-B6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1086\/502581","article-title":"Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance","volume":"26","author":"Morgan","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026091805324048100_ofag563-B7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/11584810-000000000-00000","article-title":"Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients","volume":"29","author":"Reboli","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"2026091805324048100_ofag563-B8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091805324048100_ofag563-B9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026091805324048100_ofag563-B10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2026091805324048100_ofag563-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18 Suppl 7","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026091805324048100_ofag563-B12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10096-022-04473-w","article-title":"Development of the invasive candidiasis discharge [I can discharge] model: a mixed methods analysis","volume":"41","author":"Jo","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026091805324048100_ofag563-B13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","volume":"23","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026091805324048100_ofag563-B14","doi-asserted-by":"crossref","first-page":"ofad703","DOI":"10.1093\/ofid\/ofad703","article-title":"Healthcare resource utilization and discharge readiness in adult hospitalized patients with candidemia or invasive candidiasis who received an echinocandin: an analysis of United States hospitals","volume":"11","author":"Lodise","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026091805324048100_ofag563-B15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","article-title":"Predictors for prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM Candida III Multinational European Observational Cohort Study","volume":"188","author":"Egger","year":"2023","journal-title":"Mycopathologia"},{"key":"2026091805324048100_ofag563-B16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13054-024-05152-2","article-title":"Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials","volume":"28","author":"Honor\u00e9","year":"2024","journal-title":"Crit Care"},{"key":"2026091805324048100_ofag563-B17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jac\/dkae415","article-title":"The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics","volume":"80","author":"Andes","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026091805324048100_ofag563-B18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/phar.2943","article-title":"Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate\/severe hepatic impairment and matched control subjects","volume":"44","author":"Flanagan","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2026091805324048100_ofag563-B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2026091805324048100_ofag563-B20","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026091805324048100_ofag563-B21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805324048100_ofag563-B22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMp1500445","article-title":"Setting value-based payment goals\u2013HHS efforts to improve U.S. Health care","volume":"372","author":"Burwell","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091805324048100_ofag563-B23","author":"Centers for Disease Control and Prevention"},{"key":"2026091805324048100_ofag563-B24","doi-asserted-by":"crossref","first-page":"e2125846","DOI":"10.1001\/jamanetworkopen.2021.25846","article-title":"Interventions to reduce hospital length of stay in high-risk populations: a systematic review","volume":"4","author":"Siddique","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026091805324048100_ofag563-B25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.15441\/ceem.18.022","article-title":"Emergency department and hospital crowding: causes, consequences, and cures","volume":"6","author":"McKenna","year":"2019","journal-title":"Clin Exp Emerg Med"},{"key":"2026091805324048100_ofag563-B26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jemermed.2010.06.028","article-title":"The relationship between inpatient discharge timing and emergency department boarding","volume":"42","author":"Powell","year":"2012","journal-title":"J Emerg Med"},{"key":"2026091805324048100_ofag563-B27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1197\/aemj.10.2.127","article-title":"The effect of hospital occupancy on emergency department length of stay and patient disposition","volume":"10","author":"Forster","year":"2003","journal-title":"Acad Emerg Med"},{"key":"2026091805324048100_ofag563-B28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1062860619846559","article-title":"Hospitalized after medical readiness for discharge: a multidisciplinary quality improvement initiative to identify discharge barriers in general medicine patients","volume":"35","author":"Meo","year":"2020","journal-title":"Am J Med Qual"},{"key":"2026091805324048100_ofag563-B29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/jhm.2591","article-title":"Not ready, not set\u2026discharge: patient-reported barriers to discharge readiness at an academic medical center","volume":"11","author":"Harrison","year":"2016","journal-title":"J Hosp Med"},{"key":"2026091805324048100_ofag563-B30","volume-title":"Merative micromedex [database online]","author":"Red Book Online","year":"2026"},{"key":"2026091805324048100_ofag563-B31","author":"U.S. Bureau of Labor Statistics"},{"key":"2026091805324048100_ofag563-B32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026091805324048100_ofag563-B33","volume-title":"Achieving hospital-wide patient flow","author":"Institute for Healthcare Improvement (IHI)","year":"2017","edition":"2nd ed"},{"key":"2026091805324048100_ofag563-B34","volume-title":"Improving patient flow and reducing emergency department crowding: a guide for hospitals","author":"McHugh","year":"2011"},{"key":"2026091805324048100_ofag563-B35","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1111\/myc.70114","article-title":"Rezafungin utilisation in real life-FungiScope results from Europe and the United States","volume":"68","author":"Reinhold","year":"2025","journal-title":"Mycoses"},{"key":"2026091805324048100_ofag563-B36","doi-asserted-by":"crossref","first-page":"ofaf034","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term safety and effectiveness of rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026091805324048100_ofag563-B37","doi-asserted-by":"crossref","first-page":"e70163","DOI":"10.1111\/myc.70163","article-title":"Rezafungin for salvage or consolidation therapy of invasive fungal disease: experience in real-world clinical practice","volume":"69","author":"Bo\u00e1n","year":"2026","journal-title":"Mycoses"},{"key":"2026091805324048100_ofag563-B38","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1017\/ash.2022.313","article-title":"Assessment of risk factors associated with outpatient parenteral antimicrobial therapy (OPAT) complications: a retrospective cohort study","volume":"2","author":"Kaul","year":"2022","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026091805324048100_ofag563-B39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jac\/dkv344","article-title":"Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study","volume":"71","author":"Shrestha","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026091805324048100_ofag563-B40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1062860619853345","article-title":"It\u2019s complicated: patient and informal caregiver performance of outpatient parenteral antimicrobial therapy-related tasks","volume":"35","author":"Keller","year":"2020","journal-title":"Am J Med Qual"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag563\/71005909\/ofag563.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag563\/71005909\/ofag563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag563\/71005909\/ofag563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:38Z","timestamp":1789724018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag563\/8788735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag563","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"ofag563"}}